{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:49:55Z","timestamp":1790959795727,"version":"4.1.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Prostate Cancer Foundation Australia\/Movember"},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","award":["MCRF16022"],"award-info":[{"award-number":["MCRF16022"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australiian Research Council","award":["FT130100671"],"award-info":[{"award-number":["FT130100671"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Rep"],"published-print":{"date-parts":[[2020,6,4]]},"DOI":"10.15252\/embr.202050162","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T06:45:48Z","timestamp":1587451548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Prostate cancer cell\u2010intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone"],"prefix":"10.1038","volume":"21","author":[{"given":"Katie L","family":"Owen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linden J","family":"Gearing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien J","family":"Zanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha K","family":"Brockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weng Hua","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Cmero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mangiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J","family":"Spurling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia\u2010Ling","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Pasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth J","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika M","family":"Duivenvoorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Mariadason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-2984","authenticated-orcid":false,"given":"Tri","family":"Giang Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Swarbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall M","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Hertzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter I","family":"Croucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hovens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-1926","authenticated-orcid":false,"given":"Belinda S","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"BFEMBR202050162_CR1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184: 162\u2013167","journal-title":"J Urol"},{"key":"BFEMBR202050162_CR2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5489\/cuaj.2707","volume":"9","author":"L Perrault","year":"2015","unstructured":"Perrault L, Fradet V, Lauzon V, LeLorier J, Mitchell D, Habib M (2015) Burden of illness of bone metastases in prostate cancer patients in Qu\u00e9bec, Canada: a population\u2010based analysis. Can Urol Assoc J 9: 307\u2013314","journal-title":"Can Urol Assoc J"},{"key":"BFEMBR202050162_CR3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccr.2012.11.010","volume":"23","author":"NL Sharma","year":"2013","unstructured":"Sharma NL, Massie CE, Ramos\u2010Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG et\u00a0al (2013) The androgen receptor induces a distinct transcriptional program in castration\u2010resistant prostate cancer in man. Cancer Cell 23: 35\u201347","journal-title":"Cancer Cell"},{"key":"BFEMBR202050162_CR4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","volume":"10","author":"DP Dearnaley","year":"2009","unstructured":"Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long\u2010term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10: 872\u2013876","journal-title":"Lancet Oncol"},{"key":"BFEMBR202050162_CR5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H et\u00a0al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration\u2010resistant prostate cancer: a randomised, double\u2010blind study. Lancet (London, England) 377: 813\u2013822","journal-title":"Lancet (London, England)"},{"key":"BFEMBR202050162_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pharmthera.2015.11.008","volume":"158","author":"HH Van Acker","year":"2016","unstructured":"Van Acker HH, Anguille S, Willemen Y, Smits EL, Van Tendeloo VF (2016) Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. Pharmacol Ther 158: 24\u201340","journal-title":"Pharmacol Ther"},{"key":"BFEMBR202050162_CR7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, Day SJO, Mcdermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Ph D, Schadendorf D, Hassel JC et\u00a0al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711\u2013723","journal-title":"N Engl J Med"},{"key":"BFEMBR202050162_CR8","first-page":"1","volume":"71","author":"EB Ylitalo","year":"2016","unstructured":"Ylitalo EB, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, Stattin P, Widmark A, Bergh A, Wikstr\u00f6m P (2016) Subgroups of castration\u2010resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response. Eur Urol 71: 1\u201312","journal-title":"Eur Urol"},{"key":"BFEMBR202050162_CR9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, Alfons JM, Den Eertwegh V, Krainer M, Houede N, Santos R et\u00a0al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration\u2010resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184\u2010043): a multicentre, randomised, double\u2010blind, phase 3 trial. Lancet 15: 700\u2013712","journal-title":"Lancet"},{"key":"BFEMBR202050162_CR10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.05.004","volume":"117","author":"Z Reinstein","year":"2017","unstructured":"Reinstein Z, Pamarthy S, Sagar V, Costa R, Abdulkadir SA, Giles FJ, Carneiro BA (2017) Overcoming immunosuppression in bone metastases. Crit Rev Oncol Hematol 117: 114\u2013127","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFEMBR202050162_CR11","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1073\/pnas.042372199","volume":"99","author":"O Solakoglu","year":"2002","unstructured":"Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Kollermann MW et\u00a0al (2002) Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA 99: 2246\u20132251","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMBR202050162_CR12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-08-1754","volume":"15","author":"TM Morgan","year":"2009","unstructured":"Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL (2009) Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 15: 677\u2013683","journal-title":"Clin Cancer Res"},{"key":"BFEMBR202050162_CR13","doi-asserted-by":"crossref","first-page":"7383","DOI":"10.1158\/0008-5472.CAN-14-0934","volume":"74","author":"M Gu\u017evi\u0107","year":"2014","unstructured":"Gu\u017evi\u0107 M, Braun B, Ganzer R, Burger M, Nerlich M, Winkler S, Werner\u2010Klein M, Czyz ZT, Polzer B, Klein CA (2014) Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes. Cancer Res 74: 7383\u20137394","journal-title":"Cancer Res"},{"key":"BFEMBR202050162_CR14","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1200\/JCO.2008.17.0563","volume":"27","author":"D Weckermann","year":"2009","unstructured":"Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, Bertz S, Harzmann R, Klein CA (2009) Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 27: 1549\u20131556","journal-title":"J Clin Oncol"},{"key":"BFEMBR202050162_CR15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2012.10.002","volume":"63","author":"M Popiolek","year":"2013","unstructured":"Popiolek M, Rider JR, Andr\u00e9n O, Andersson SO, Holmberg L, Adami HO, Johansson JE (2013) Natural history of early, localized prostate cancer: a final report from three decades of follow\u2010up. Eur Urol 63: 428\u2013435","journal-title":"Eur Urol"},{"key":"BFEMBR202050162_CR16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2016.02.002","volume":"40","author":"EE Van der Toom","year":"2016","unstructured":"Van der Toom EE, Verdone JE, Pienta KJ (2016) Disseminated tumor cells and dormancy in prostate cancer metastasis. Curr Opin Biotechnol 40: 9\u201315","journal-title":"Curr Opin Biotechnol"},{"key":"BFEMBR202050162_CR17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gde.2010.10.011","volume":"21","author":"CA Klein","year":"2011","unstructured":"Klein CA (2011) Framework models of tumor dormancy from patient\u2010derived observations. Curr Opin Genet Dev 21: 42\u201349","journal-title":"Curr Opin Genet Dev"},{"key":"BFEMBR202050162_CR18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrc3910","volume":"15","author":"CM Ghajar","year":"2015","unstructured":"Ghajar CM (2015) Metastasis prevention by targeting the dormant niche. Nat Rev Cancer 15: 238\u2013247","journal-title":"Nat Rev Cancer"},{"key":"BFEMBR202050162_CR19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre\u2010Ghiso","year":"2007","unstructured":"Aguirre\u2010Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834\u2013846","journal-title":"Nat Rev Cancer"},{"key":"BFEMBR202050162_CR20","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","volume":"18","author":"BN Bidwell","year":"2012","unstructured":"Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA et\u00a0al (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18: 1224\u20131231","journal-title":"Nat Med"},{"key":"BFEMBR202050162_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4137\/CGM.S11284","volume":"6","author":"C Hibberd","year":"2013","unstructured":"Hibberd C, Cossigny D, Quan G (2013) Animal cancer models of skeletal metastasis. Cancer Growth Metastasis 6: 23\u201334","journal-title":"Cancer Growth Metastasis"},{"key":"BFEMBR202050162_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers10060176","volume":"10","author":"AH Jinnah","year":"2018","unstructured":"Jinnah AH, Zacks BC, Gwam CU, Kerr BA (2018) Emerging and established models of bone metastasis. Cancers (Basel) 10: 1\u201315","journal-title":"Cancers (Basel)"},{"key":"BFEMBR202050162_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-016-0930-3","volume":"17","author":"CA Vallejos","year":"2016","unstructured":"Vallejos CA, Richardson S, Marioni JC (2016) Beyond comparisons of means: understanding changes in gene expression at the single\u2010cell level. Genome Biol 17: 1\u201314","journal-title":"Genome Biol"},{"key":"BFEMBR202050162_CR24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.cels.2018.06.011","volume":"7","author":"N Eling","year":"2018","unstructured":"Eling N, Richard AC, Richardson S, Marioni JC, Vallejos CA (2018) Correcting the mean\u2010variance dependency for differential variability testing using single\u2010cell RNA sequencing data. Cell Syst 7: 284\u2013294.e12","journal-title":"Cell Syst"},{"key":"BFEMBR202050162_CR25","doi-asserted-by":"crossref","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","volume":"41","author":"I Rusinova","year":"2013","unstructured":"Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R, Hertzog PJ (2013) Interferome v2.0: an updated database of annotated interferon\u2010regulated genes. Nucleic Acids Res 41: D1040\u2013D1046","journal-title":"Nucleic Acids Res"},{"key":"BFEMBR202050162_CR26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nature03464","volume":"434","author":"K Honda","year":"2005","unstructured":"Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N et\u00a0al (2005) IRF\u20107 is the master regulator of type\u2010I interferon\u2010dependent immune responses. Nature 434: 772\u2013777","journal-title":"Nature"},{"key":"BFEMBR202050162_CR27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/bioinformatics\/btm134","volume":"23","author":"H Kim","year":"2007","unstructured":"Kim H, Park H (2007) Sparse non\u2010negative matrix factorizations via alternating non\u2010negativity\u2010constrained least squares for microarray data analysis. Bioinformatics 23: 1495\u20131502","journal-title":"Bioinformatics"},{"key":"BFEMBR202050162_CR28","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1158\/0008-5472.CAN-15-1370","volume":"75","author":"AC Yeh","year":"2015","unstructured":"Yeh AC, Ramaswamy S (2015) Mechanisms of cancer cell dormancy\u2014another hallmark of cancer? Cancer Res 75: 5014\u20135022","journal-title":"Cancer Res"},{"key":"BFEMBR202050162_CR29","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.18632\/oncotarget.2480","volume":"5","author":"L Ch\u00e9ry","year":"2014","unstructured":"Ch\u00e9ry L, Lam H\u2010M, Coleman I, Lakely B, Coleman R, Larson S, Aguirre\u2010Ghiso JA, Xia J, Gulati R, Nelson PS et\u00a0al (2014) Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget 5: 9939\u20139951","journal-title":"Oncotarget"},{"key":"BFEMBR202050162_CR30","first-page":"1","volume":"7","author":"RS Kim","year":"2012","unstructured":"Kim RS, Avivar\u2010Valderas A, Estrada Y, Bragado P, Sosa MS, Aguirre\u2010Ghiso JA, Segall JE (2012) Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS ONE 7: 1\u20138","journal-title":"PLoS ONE"},{"key":"BFEMBR202050162_CR31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/1541-7786.MCR-18-0956","volume":"17","author":"J McGrath","year":"2019","unstructured":"McGrath J, Panzica L, Ransom R, Withers HG, Gelman IH (2019) Identification of genes regulating breast cancer dormancy in 3d bone endosteal niche cultures. Mol Cancer Res 17: 860\u2013869","journal-title":"Mol Cancer Res"},{"key":"BFEMBR202050162_CR32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrc3793","volume":"14","author":"MS Sosa","year":"2014","unstructured":"Sosa MS, Bragado P, Aguirre\u2010Ghiso JA (2014) Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 14: 611\u2013622","journal-title":"Nat Rev Cancer"},{"key":"BFEMBR202050162_CR33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1593\/neo.91384","volume":"12","author":"Y Shiozawa","year":"2010","unstructured":"Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ et\u00a0al (2010) GAS6\/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12: 116\u2013127","journal-title":"Neoplasia"},{"key":"BFEMBR202050162_CR34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker BS, Rautela J, Hertzog PJ (2016) Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 16: 131\u2013144","journal-title":"Nat Rev Cancer"},{"key":"BFEMBR202050162_CR35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P (2015) The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst 1: 417\u2013425","journal-title":"Cell Syst"},{"key":"BFEMBR202050162_CR36","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1074\/jbc.M116.756510","volume":"292","author":"W Li","year":"2017","unstructured":"Li W, Hofer MJ, Songkhunawej P, Jung SR, Hancock D, Denyer G, Campbell IL (2017) Type I interferon\u2010regulated gene expression and signaling in murine mixed glial cells lacking signal transducers and activators of transcription 1 or 2 or interferon regulatory factor 9. J Biol Chem 292: 5845\u20135859","journal-title":"J Biol Chem"},{"key":"BFEMBR202050162_CR37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41698-019-0093-2","volume":"3","author":"NK Brockwell","year":"2019","unstructured":"Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan C\u2010L, Cumming HE et\u00a0al (2019) Tumor inherent interferon regulators as biomarkers of long\u2010term chemotherapeutic response in TNBC. NPJ Precis Oncol 3: 21","journal-title":"NPJ Precis Oncol"},{"key":"BFEMBR202050162_CR38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1074\/mcp.M113.035600","volume":"13","author":"L Fagerberg","year":"2014","unstructured":"Fagerberg L, Hallstro M, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K et\u00a0al (2014) Analysis of the human tissue\u2010specific expression by genome\u2010wide integration of transcriptomics and antibody\u2010based. Mol Cell Proteomics 13: 397\u2013406","journal-title":"Mol Cell Proteomics"},{"key":"BFEMBR202050162_CR39","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/j.1538-7836.2011.04530.x","volume":"9","author":"S Negrotto","year":"2011","unstructured":"Negrotto S, Giusti CJDE, Lapponi MJ, Etulain J, Rivadeneyra L, Pozner RG (2011) Expression and functionality of type I interferon receptor in the megakaryocytic lineage. J Thromb Haemost 9: 2477\u20132485","journal-title":"J Thromb Haemost"},{"key":"BFEMBR202050162_CR40","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1038\/cddis.2013.5","volume":"4","author":"AR Bernardo","year":"2013","unstructured":"Bernardo AR, Cosgaya JM, Aranda A, Jim\u00e9nez\u2010Lara AM (2013) Synergy between RA and TLR3 promotes type I IFN\u2010dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells. Cell Death Dis 4: e479","journal-title":"Cell Death Dis"},{"key":"BFEMBR202050162_CR41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1089\/jir.2005.25.745","volume":"25","author":"I Nusinzon","year":"2005","unstructured":"Nusinzon I, Horvath CM (2005) Unexpected roles for deacetylation in interferon\u2010 and cytokine\u2010induced transcription. J Interferon Cytokine Res 25: 745\u2013748","journal-title":"J Interferon Cytokine Res"},{"key":"BFEMBR202050162_CR42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/gene.2011.21","volume":"12","author":"S Ning","year":"2011","unstructured":"Ning S, Pagano JS, Barber GN (2011) IRF7: activation, regulation, modification and function. Genes Immun 12: 399\u2013414","journal-title":"Genes Immun"},{"key":"BFEMBR202050162_CR43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14: 36\u201345","journal-title":"Nat Rev Immunol"},{"key":"BFEMBR202050162_CR44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2051-1426-1-10","volume":"1","author":"R Wesolowski","year":"2013","unstructured":"Wesolowski R, Markowitz J, Carson WE (2013) Myeloid derived suppressor cells \u2013 a new therapeutic target in the treatment of cancer. J Immunother Cancer 1: 10","journal-title":"J Immunother Cancer"},{"key":"BFEMBR202050162_CR45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdw599.002","volume":"27","author":"N Mehra","year":"2016","unstructured":"Mehra N, Seed G, Lambros M, Sharp A, Fontes MS, Crespo M, Sumanasuriya S, Yuan W, Boysen G, Riisnaes R et\u00a0al (2016) Myeloid\u2010derived suppressor cells (MDSCs) in metastatic castration\u2010resistant prostate cancer (CRPC) patients (PTS). Ann Oncol 27: 243\u2013265","journal-title":"Ann Oncol"},{"key":"BFEMBR202050162_CR46","doi-asserted-by":"crossref","first-page":"57452","DOI":"10.18632\/oncotarget.10767","volume":"7","author":"C Zhang","year":"2016","unstructured":"Zhang C, Wang S, Liu Y, Yang C (2016) Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer. Oncotarget 7: 57452\u201357463","journal-title":"Oncotarget"},{"key":"BFEMBR202050162_CR47","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","volume":"41","author":"M Andreoiu","year":"2010","unstructured":"Andreoiu M, Cheng L (2010) Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 41: 781\u2013793","journal-title":"Hum Pathol"},{"key":"BFEMBR202050162_CR48","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2015","unstructured":"Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, Annala M, Aprikian A, Armenia J, Arora A et\u00a0al (2015) The molecular taxonomy of primary prostate cancer. Cell 163: 1011\u20131025","journal-title":"Cell"},{"key":"BFEMBR202050162_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02674-y","volume":"9","author":"M Werner\u2010klein","year":"2018","unstructured":"Werner\u2010klein M, Scheitler S, Hoffmann M, Hodak I, Dietz K, Lehnert P, Naimer V, Polzer B, Treitschke S, Werno C et\u00a0al (2018) Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun 9: 1\u201317","journal-title":"Nat Commun"},{"key":"BFEMBR202050162_CR50","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, H\u00f6gn\u00e4s G, Annala M et\u00a0al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520: 353","journal-title":"Nature"},{"key":"BFEMBR202050162_CR51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","volume":"127","author":"GP Gupta","year":"2006","unstructured":"Gupta GP, Massagu\u00e9 J (2006) Cancer metastasis: building a framework. Cell 127: 679\u2013695","journal-title":"Cell"},{"key":"BFEMBR202050162_CR52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1593\/neo.07112","volume":"9","author":"DR Rhodes","year":"2007","unstructured":"Rhodes DR, Kalyana\u2010Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead\u2010Beal C, Kulkarni P et\u00a0al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9: 166\u2013180","journal-title":"Neoplasia"},{"key":"BFEMBR202050162_CR53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccr.2005.10.001","volume":"8","author":"S Varambally","year":"2005","unstructured":"Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et\u00a0al (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393\u2013406","journal-title":"Cancer Cell"},{"key":"BFEMBR202050162_CR54","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1158\/0008-5472.CAN-04-2442","volume":"64","author":"RB Shah","year":"2004","unstructured":"Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, MacVicar GR, Varambally S, Harwood J, Bismar TA et\u00a0al (2004) Androgen\u2010independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64: 9209\u20139216","journal-title":"Cancer Res"},{"key":"BFEMBR202050162_CR55","doi-asserted-by":"crossref","first-page":"33918","DOI":"10.1038\/srep33918","volume":"6","author":"S Mangiola","year":"2016","unstructured":"Mangiola S, Hong MKH, Cmero M, Kurganovs N, Ryan A, Costello AJ, Corcoran NM, Macintyre G, Hovens CM (2016) Comparing nodal versus bony metastatic spread using tumour phylogenies. Sci Rep 6: 33918","journal-title":"Sci Rep"},{"key":"BFEMBR202050162_CR56","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","volume":"6","author":"MKH Hong","year":"2015","unstructured":"Hong MKH, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F et\u00a0al (2015) Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6: 6605","journal-title":"Nat Commun"},{"key":"BFEMBR202050162_CR57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cytogfr.2013.04.002","volume":"24","author":"PJ Hertzog","year":"2013","unstructured":"Hertzog PJ, Williams BRG (2013) Fine tuning type I interferon responses. Cytokine Growth Factor Rev 24: 217\u2013225","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFEMBR202050162_CR58","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ni.2468","volume":"13","author":"DM Andrews","year":"2012","unstructured":"Andrews DM, Sullivan LC, Baschuk N, Chan CJ, Berry R, Cotterell CL, Lin J, Halse H, Watt SV, Poursine\u2010Laurent J et\u00a0al (2012) Recognition of the nonclassical MHC class I molecule H2\u2010M3 by the receptor Ly49A regulates the licensing and activation of NK cells. Nat Immunol 13: 1171\u20131177","journal-title":"Nat Immunol"},{"key":"BFEMBR202050162_CR59","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/ijms18071542","volume":"18","author":"G Bryant","year":"2017","unstructured":"Bryant G, Wang L, Mulholland DJ (2017) Overcoming oncogenic mediated tumor immunity in prostate cancer. Int J Mol Sci 18: 1542","journal-title":"Int J Mol Sci"},{"key":"BFEMBR202050162_CR60","doi-asserted-by":"crossref","first-page":"794968","DOI":"10.1155\/2015\/794968","volume":"2015","author":"I Silvestri","year":"2015","unstructured":"Silvestri I, Cattarino S, Aglian\u00f2 AM, Collalti G, Sciarra A (2015) Beyond the immune suppression: the immunotherapy in prostate cancer. Biomed Res Int 2015: 794968","journal-title":"Biomed Res Int"},{"key":"BFEMBR202050162_CR61","first-page":"1741","volume":"6","author":"P Li","year":"2016","unstructured":"Li P, Jia Y\u2010F, Ma X\u2010L, Zheng Y, Kong Y, Zhang Y, Zong S, Chen Z\u2010T, Wang Y\u2010S (2016) DEC2 suppresses tumor proliferation and metastasis by regulating ERK\/NF\u2010\u03baB pathway in gastric cancer. Am J Cancer Res 6: 1741\u20131757","journal-title":"Am J Cancer Res"},{"key":"BFEMBR202050162_CR62","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cell.2017.04.018","volume":"169","author":"N Cabezas\u2010wallscheid","year":"2017","unstructured":"Cabezas\u2010wallscheid N, Buettner F, Sommerkamp P, Rieger MA, Stegle O, Cabezas\u2010wallscheid N, Buettner F, Sommerkamp P, Klimmeck D, Ladel L et\u00a0al (2017) Vitamin A\u2010retinoic acid signaling regulates hematopoietic stem cell dormancy article vitamin A\u2010retinoic acid signaling regulates hematopoietic stem cell dormancy. Cell 169: 807\u2013823","journal-title":"Cell"},{"key":"BFEMBR202050162_CR63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","volume":"16","author":"V Plaks","year":"2015","unstructured":"Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16: 225\u2013238","journal-title":"Cell Stem Cell"},{"key":"BFEMBR202050162_CR64","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3389\/fonc.2018.00505","volume":"8","author":"X Yang","year":"2018","unstructured":"Yang X, Liang X, Zheng M, Tang Y (2018) Cellular phenotype plasticity in cancer dormancy and metastasis. Front Oncol 8: 505","journal-title":"Front Oncol"},{"key":"BFEMBR202050162_CR65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fonc.2018.00072","volume":"8","author":"AS Yadav","year":"2018","unstructured":"Yadav AS, Pandey PR, Butti R, Radharani NNV, Roy S, Bhalara SR, Gorain M, Kundu GC, Kumar D (2018) The biology and therapeutic implications of tumor dormancy and reactivation. Front Oncol 8: 72","journal-title":"Front Oncol"},{"key":"BFEMBR202050162_CR66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","volume":"39","author":"J Galon","year":"2013","unstructured":"Galon J, Angell H, Bedognetti D, Marincola F (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39: 11\u201326","journal-title":"Immunity"},{"key":"BFEMBR202050162_CR67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","volume":"7","author":"H Takayanagi","year":"2007","unstructured":"Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292\u2013304","journal-title":"Nat Rev Immunol"},{"key":"BFEMBR202050162_CR68","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/eji.201040895","volume":"40","author":"J\u2010I Youn","year":"2010","unstructured":"Youn J\u2010I, Gabrilovich DI (2010) The biology of myeloid\u2010derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40: 2969\u20132975","journal-title":"Eur J Immunol"},{"key":"BFEMBR202050162_CR69","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-12-2202","volume":"73","author":"A Sawant","year":"2013","unstructured":"Sawant A, Deshane J, Jules J, Lee CM, Harris BA, Feng X, Ponnazhagan S (2013) Myeloid\u2010derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res 73: 672\u2013682","journal-title":"Cancer Res"},{"key":"BFEMBR202050162_CR70","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1530\/ERC-16-0404","volume":"24","author":"AMK Law","year":"2017","unstructured":"Law AMK, Lim E, Ormandy CJ, Gallego\u2010Ortega D (2017) The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocr Relat Cancer 24: R123\u2013R144","journal-title":"Endocr Relat Cancer"},{"key":"BFEMBR202050162_CR71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12967-015-0410-7","volume":"13","author":"L\u2010Y OuYang","year":"2015","unstructured":"OuYang L\u2010Y, Wu X\u2010J, Ye S\u2010B, Zhang R, Li Z\u2010L, Liao W, Pan Z\u2010Z, Zheng L\u2010M, Zhang X\u2010S, Wang Z et\u00a0al (2015) Tumor\u2010induced myeloid\u2010derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med 13: 47","journal-title":"J Transl Med"},{"key":"BFEMBR202050162_CR72","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","volume":"23","author":"A Orillion","year":"2017","unstructured":"Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye\u2010Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B et\u00a0al (2017) Entinostat neutralizes myeloid\u2010derived suppressor cells and enhances the antitumor effect of PD\u20101 inhibition in murine models of lung and renal cell carcinoma. Clin Cancer Res 23: 5187\u20135201","journal-title":"Clin Cancer Res"},{"key":"BFEMBR202050162_CR73","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrc3246","volume":"12","author":"T Blankenstein","year":"2012","unstructured":"Blankenstein T, Coulie PG, Gilboa E, Jaffee EM (2012) The determinants of tumour immunogenicity. Nat Rev Cancer 12: 307\u2013313","journal-title":"Nat Rev Cancer"},{"key":"BFEMBR202050162_CR74","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.eururo.2016.07.033","volume":"71","author":"EB Ylitalo","year":"2017","unstructured":"Ylitalo EB, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, Stattin P, Widmark A, Bergh A, Wikstr\u00f6m P (2017) Subgroups of castration\u2010resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response. Eur Urol 71: 776\u2013787","journal-title":"Eur Urol"},{"key":"BFEMBR202050162_CR75","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","volume":"29","author":"H Tang","year":"2016","unstructured":"Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Wang X, Fu Y\u2010X (2016) Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD\u2010L1 blockade. Cancer Cell 29: 285\u2013296","journal-title":"Cancer Cell"},{"key":"BFEMBR202050162_CR76","first-page":"10344214","volume":"39","author":"K Koeneman","year":"2014","unstructured":"Koeneman K, Yeung F, Chung LWK (2014) Osteomimetic properties of prostate cancer cells : a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 10344214","journal-title":"Prostate"},{"key":"BFEMBR202050162_CR77","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1158\/0008-5472.CAN-04-3448","volume":"65","author":"WC Huang","year":"2005","unstructured":"Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LWK (2005) Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP\u2010dependent protein kinase A signaling pathway. Cancer Res 65: 2303\u20132313","journal-title":"Cancer Res"},{"key":"BFEMBR202050162_CR78","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jcb.10662","volume":"91","author":"ET Keller","year":"2004","unstructured":"Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91: 718\u2013729","journal-title":"J Cell Biochem"},{"key":"BFEMBR202050162_CR79","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jbmr.1749","volume":"28","author":"C Morrissey","year":"2013","unstructured":"Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL (2013) Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration\u2010resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res 28: 333\u2013340","journal-title":"J Bone Miner Res"},{"key":"BFEMBR202050162_CR80","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ajpath.2012.03.023","volume":"181","author":"M Wilkison","year":"2012","unstructured":"Wilkison M, Gauss K, Ran Y, Searles S, Taylor D, Meissner N (2012) Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection. Am J Pathol 181: 151\u2013162","journal-title":"Am J Pathol"},{"key":"BFEMBR202050162_CR81","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1016\/j.febslet.2012.06.047","volume":"586","author":"J Zhang","year":"2012","unstructured":"Zhang J, Zhao H, Chen J, Xia B, Jin Y, Wei W, Shen J, Huang Y (2012) Interferon\u2010\u03b2\u2010induced miR\u2010155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett 586: 3255\u20133262","journal-title":"FEBS Lett"},{"key":"BFEMBR202050162_CR82","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Rem\u00e9dios C et\u00a0al (2014) Cancer cell\u2013autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20: 1301","journal-title":"Nat Med"},{"key":"BFEMBR202050162_CR83","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/bjc.2015.398","volume":"114","author":"M\u2010E Legrier","year":"2016","unstructured":"Legrier M\u2010E, Bi\u00e8che I, Gaston J, Beurdeley A, Yvonnet V, D\u00e9as O, Thuleau A, Ch\u00e2teau\u2010Joubert S, Servely J\u2010L, Vacher S et\u00a0al (2016) Activation of IFN\/STAT1 signalling predicts response to chemotherapy in oestrogen receptor\u2010negative breast cancer. Br J Cancer 114: 177\u2013187","journal-title":"Br J Cancer"},{"key":"BFEMBR202050162_CR84","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41467-017-00608-2","volume":"8","author":"N Jacquelot","year":"2017","unstructured":"Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Tern\u00e8s N, Jegou S, Woods DM, Sodr\u00e9 AL, Hansen M, Meirow Y et\u00a0al (2017) Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 8: 592","journal-title":"Nat Commun"},{"key":"BFEMBR202050162_CR85","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/2326-6066.CIR-17-0150","volume":"5","author":"NK Brockwell","year":"2017","unstructured":"Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK et\u00a0al (2017) Neoadjuvant interferons: critical for effective PD\u20101 based immunotherapy in TNBC. Cancer Immunol Res 5: 871\u2013884","journal-title":"Cancer Immunol Res"},{"key":"BFEMBR202050162_CR86","first-page":"1","volume":"6","author":"Y Li","year":"2017","unstructured":"Li Y, Seto E (2017) HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 6: 1\u201334.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"BFEMBR202050162_CR87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124: 30\u201339","journal-title":"J Clin Invest"},{"key":"BFEMBR202050162_CR88","doi-asserted-by":"crossref","first-page":"83155","DOI":"10.18632\/oncotarget.17950","volume":"8","author":"L Booth","year":"2017","unstructured":"Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P (2017) HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget 8: 83155\u201383170","journal-title":"Oncotarget"},{"key":"BFEMBR202050162_CR89","doi-asserted-by":"crossref","first-page":"114156","DOI":"10.18632\/oncotarget.23169","volume":"8","author":"M Terranova\u2010Barberio","year":"2017","unstructured":"Terranova\u2010Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN (2017) HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget 8: 114156\u2013114172","journal-title":"Oncotarget"},{"key":"BFEMBR202050162_CR90","doi-asserted-by":"crossref","first-page":"14742","DOI":"10.1073\/pnas.2433987100","volume":"100","author":"I Nusinzon","year":"2003","unstructured":"Nusinzon I, Horvath CM (2003) Interferon\u2010stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA 100: 14742\u201314747","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMBR202050162_CR91","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/cmi.2012.28","volume":"9","author":"X Zhang","year":"2012","unstructured":"Zhang X, Han S, Kang Y, Guo M, Hong S, Liu F, Fu S, Wang L, Wang QX (2012) SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection. Cell Mol Immunol 9: 390\u2013398","journal-title":"Cell Mol Immunol"},{"key":"BFEMBR202050162_CR92","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/mt.2012.265","volume":"21","author":"BW Bridle","year":"2013","unstructured":"Bridle BW, Chen L, Lemay CG, Diallo J\u2010S, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC et\u00a0al (2013) HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 21: 887\u2013894","journal-title":"Mol Ther"},{"key":"BFEMBR202050162_CR93","first-page":"1","volume":"7","author":"CL Ihle","year":"2019","unstructured":"Ihle CL, Provera MD, Straign DM, Smith EE, Edgerton SM, Van Bokhoven A, Lucia MS, Owens P (2019) Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. J Immunother Cancer 7: 1\u20139","journal-title":"J Immunother Cancer"},{"key":"BFEMBR202050162_CR94","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon\u2010Christersson J et\u00a0al (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577: 561\u2013565","journal-title":"Nature"},{"key":"BFEMBR202050162_CR95","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10585-013-9617-2","volume":"31","author":"MKH Hong","year":"2014","unstructured":"Hong MKH, Sapre N, Phal PM, MacIntyre G, Chin X, Pedersen JS, Ryan A, Kerger M, Costello AJ, Corcoran NM et\u00a0al (2014) Percutaneous image\u2010guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology. Clin Exp Metastasis 31: 159\u2013167","journal-title":"Clin Exp Metastasis"},{"key":"BFEMBR202050162_CR96","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/nbt.3674","volume":"34","author":"K Alsop","year":"2016","unstructured":"Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L et\u00a0al (2016) A community\u2010based model of rapid autopsy in end\u2010stage cancer patients. Nat Biotechnol 34: 1010\u20131014","journal-title":"Nat Biotechnol"},{"key":"BFEMBR202050162_CR97","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA\u2010seq aligner. Bioinformatics 29: 15\u201321","journal-title":"Bioinformatics"},{"key":"BFEMBR202050162_CR98","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA\u2010Seq data with or without a reference genome. BMC Bioinformatics 12: 323","journal-title":"BMC Bioinformatics"},{"key":"BFEMBR202050162_CR99","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL (2013) TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14: R36","journal-title":"Genome Biol"},{"key":"BFEMBR202050162_CR100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W (2015) HTSeq\u2014a Python framework to work with high\u2010throughput sequencing data. Bioinformatics 31: 166\u2013169","journal-title":"Bioinformatics"},{"key":"BFEMBR202050162_CR101","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26: 139\u2013140","journal-title":"Bioinformatics"},{"key":"BFEMBR202050162_CR102","first-page":"pl1","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et\u00a0al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1","journal-title":"Sci Signal"},{"key":"BFEMBR202050162_CR103","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et\u00a0al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401\u2013404","journal-title":"Cancer Discov"},{"key":"BFEMBR202050162_CR104","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1093\/nar\/gks461","volume":"40","author":"D Wu","year":"2012","unstructured":"Wu D, Smyth GK (2012) Camera: a competitive gene set test accounting for inter\u2010gene correlation. Nucleic Acids Res 40: e133","journal-title":"Nucleic Acids Res"},{"key":"BFEMBR202050162_CR105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT et\u00a0al (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25\u201329","journal-title":"Nat Genet"},{"key":"BFEMBR202050162_CR106","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et\u00a0al (2005) Gene set enrichment analysis: a knowledge\u2010based approach for interpreting genome\u2010wide expression profiles. Proc Natl Acad Sci USA 102: 15545\u201315550","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMBR202050162_CR107","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/nprot.2013.092","volume":"8","author":"H Mi","year":"2013","unstructured":"Mi H, Muruganujan A, Casagrande JT, Thomas PD (2013) Large\u2010scale gene function analysis with the PANTHER classification system. Nat Protoc 8: 1551","journal-title":"Nat Protoc"},{"key":"BFEMBR202050162_CR108","doi-asserted-by":"crossref","first-page":"D183","DOI":"10.1093\/nar\/gkw1138","volume":"45","author":"H Mi","year":"2017","unstructured":"Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, Thomas PD (2017) PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res 45: D183\u2013D189","journal-title":"Nucleic Acids Res"},{"key":"BFEMBR202050162_CR109","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1530\/EC-19-0029","volume":"8","author":"S Mangiola","year":"2019","unstructured":"Mangiola S, Stuchbery R, McCoy P, Chow K, Kurganovs N, Kerger M, Papenfuss A, Hovens CM, Corcoran NM (2019) Androgen deprivation therapy promotes an obesity\u2010like microenvironment in periprostatic fat. Endocr Connect 8: 518\u2013527","journal-title":"Endocr Connect"},{"key":"BFEMBR202050162_CR110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12: 453\u2013457","journal-title":"Nat Methods"},{"key":"BFEMBR202050162_CR111","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ymeth.2007.01.003","volume":"42","author":"P Houghton","year":"2007","unstructured":"Houghton P, Fang R, Techatanawat I, Steventon G, Hylands PJ, Lee CC (2007) The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. Methods 42: 377\u2013387","journal-title":"Methods"},{"key":"BFEMBR202050162_CR112","doi-asserted-by":"crossref","first-page":"8","DOI":"10.18632\/oncotarget.4714","volume":"6","author":"LE Edgington\u2010Mitchell","year":"2015","unstructured":"Edgington\u2010Mitchell LE, Rautela J, Duivenvoorden HM, Jayatilleke KM, van der Linden WA, Verdoes M, Bogyo M, Parker BS (2015) Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid\u2010derived suppressor cells in breast cancer. Oncotarget 6: 8\u201310","journal-title":"Oncotarget"},{"key":"BFEMBR202050162_CR113","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","volume":"6","author":"MA Lawson","year":"2015","unstructured":"Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton\u2010Hough J, Fellows C, Pettitt JA et\u00a0al (2015) Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun 6: 8983","journal-title":"Nat Commun"}],"container-title":["The EMBO Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/embr.202050162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/embr.202050162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/embr.202050162\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/embr.202050162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/embr.202050162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:40:30Z","timestamp":1779111630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/embr.202050162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":113,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,4]]}},"alternative-id":["BFEMBR202050162"],"URL":"https:\/\/doi.org\/10.15252\/embr.202050162","relation":{},"ISSN":["1469-221X","1469-3178"],"issn-type":[{"value":"1469-221X","type":"print"},{"value":"1469-3178","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare. BSP obtained commercial funding for an independent project from AstraZeneca\/MedImmune.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"EMBR202050162"}}